Transcript for 118 pharmaceutical companies sunbathe in the third quarter! 12 first losses, Murray, Changchun high-new... Nine companies made more than $2 billion, and the three bucked the market

With the listed companies in the results closed, the third quarter of the report also followed closely.
As of the close of trading on October 16, a total of 118 pharmaceutical-related enterprises in A-shares disclosed their third-quarter results, and six companies, including Zhifei Bio, People's Tongtai, Jianyou Shares and Erkang Pharmaceuticals, officially released their third-quarter results;
Among them, Meirui Medical, Xin and Cheng, Changchun Gaoxin and other 9 net profit of more than 2 billion yuan, Toling Pharmaceuticals is expected to break through the 1 billion mark;
A-share pharmaceutical enterprises in 2020 three-quarter results A-share pharmaceutical enterprises in 2020 three-quarter results forecast Mei Rui, Changchun high-tech ... 9 companies making more than $2 billion! To Ling Jin 1 billion ladder team from the disclosed third-quarter results, nearly 60% of the pre-happy, of which, Zhifei Bio officially released three-quarter results, net profit reached 2.479 billion yuan;
: The company's net profit in the first three quarters is expected to exceed the 5 billion mark.
For the performance of a substantial increase, Murray Medical said, into the third quarter, by the new crown epidemic continued to spread around the world, the international market demand for related anti-epidemic products such as monitors, ventilators, infusion pumps, new crown antibody reagents and other maintained a high level, the company's product influence is also increasing;
same time, the company continued to strengthen internal management, improve operating efficiency, during the outbreak using online promotion and other means of marketing promotion, travel expenses and other operating expenses can be effectively controlled, net profit continued to show healthy and strong growth.
In addition, the international market demand for anti-epidemic products is still large, and in order to cope with the second wave of the epidemic, some countries have begun to prepare to increase the deployment of medical system construction, in addition to the gradual recovery of conventional business, in order to prevent the outbreak of secondary outbreaks and strengthen the construction of major epidemic treatment capacity, all over the country has also launched a medical replacement board planning, the company will usher in better development opportunities.
expects the company's operating income to be RMB19.87 billion to RMB21.52 billion in 2020, up 20% to 30% YoY, and net profit of RMB6.08 billion to RMB6.55 billion, up 30% to 40% YoY.
: Net profit for the first three quarters is expected to exceed 2 billion yuan, up 75% to 85% year-on-year, surpassing last year's full-year level.
In response, Changchun Gaoxin said that the growth in performance is on the one hand the revenue growth of the holding backbone pharmaceutical enterprises, on the other hand, the company in 2019 to implement a major asset restructuring, in November 2019 completed the acquisition of 29.5% of the minority shareholders in Changchun Jinsai Pharmaceuticals, so the company from November 2019 on the basis of a shareholding of 99.5% of the financial statements of Changchun Jinsai Pharmaceuticals.
: The company expects net profit for the first three quarters to be RMB1.030 billion to RMB1,091 million, up 70% to 80% YoY.
's rapid growth was mainly due to the company's growth in revenue from its main business in the first three quarters compared with a year earlier, lower expenses and bad debt losses in each period compared to the same period a year earlier, good trends in the main business, in addition, the company enjoyed an investment income of 45% of the investment ratio after the GDS equity transfer, resulting in a significant improvement in the first three quarters.
it is worth mentioning that in 2018, Shanghai Laix due to securities investment caused a large loss, resulting in a loss of performance, net profit of more than 1.5 billion yuan. after the
experienced a severe blow, Shanghai Lais said that the company will no longer participate in new securities investment, the original securities investment will be gradually realized at the appropriate time to withdraw, the future will no longer carry out securities investment, the company's strategy and development will focus on the main business of blood products and biological products-related industries of deep cultivation and refinement, 2019 net profit of 608 million yuan.
: Net profit for the first three quarters is expected to grow 70% to 80% year-on-year and is expected to break through the 1 billion mark.
said sales of Lianhua Qing plague products increased significantly year-on-year, while sales of cardiovascular products increased year-on-year.
data show that Lianhua Qing plague products are the national basic drug catalog and the national health insurance catalogue (Class A) varieties, mainly used for the treatment of colds, influenza-related diseases.
The product has been repeatedly included by the National Health And Wellness Commission, the State Administration of Traditional Chinese Medicine in the diagnosis and treatment program of cold, influenza-related diseases; Four/five/six/seven/eight editions) recommended drug use, in April this year, the State Drug Administration approved Lianhua Qing plague capsules / particles in the original approval of the adaptation, on the basis of the addition of "new coronavirus pneumonia light, ordinary type" of the new adaptation.
the first half of 2020, Lianhua Qing plague products achieved operating income of 2,024 million yuan, accounting for 45.11% of the company's total operating income.
, Lianhua Qing plague capsules have been approved by the National Drug Administration of Uganda, so far, Lianhua Qing plague capsules have been registered in Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand and other countries and regions in the "Chinese medicine", "drug", "plant medicine", "natural health products", "food supplements" and other status registration.
24 net profit losses, 12 first-time losses So far, 24 pharmaceutical companies are expected to lose net profit, 12 first-time losses.
more than 10 enterprises, including Meiying Health, International Medicine, Zixin Pharmaceuticals, ST Tiansheng, etc., lost more than 100 million yuan.
: In the first three quarters of this year, the company forecast a net profit loss of 580 million to 430 million yuan, down 229% to 196% YoY, and a net profit of nearly 400 million yuan in the same period last year.
Health said the company's income level was low from February to April under the pressure of the outbreak, and revenue rebounded significantly in May and June, with overall revenue expected to return to the same period last year in the third quarter.
company in the consolidation of the advantages of the existing group inspection market at the same time, vigorously explore a testing market and high-quality channels, increase efforts to develop large-scale high-quality customer group orders, further improve professional medical examination and health management services, strengthen product innovation and research and development work, in the field of nucleic acid testing and screening made a significant breakthrough, thereby driving the company's revenue and profits.
In addition, the company further strengthened the medical quality control and management system, but due to the larger size of the national medical examination center, fixed costs such as housing rent, staff wages, financial expenses, equipment depreciation and decoration amortization base is still large, to the company's profits bring some pressure.
Zixin Pharmaceuticals: Affected by the epidemic, the company's main business income and profits in the first half of the year, operating results showed losses;
, the company Liuhe Pharmaceutical Industrial Park and other projects have reached the state of use, related depreciation costs increased.
plans to carry out large-scale ginseng inventory and other related products sales in the second half of the year, but there are still uncertainties, the company's board of directors based on the principle of prudence, the company's first three quarters of this year's results are expected to lose 320 million to 290 million yuan, down 536.13 percent to 495.25 percent year-on-year.